Xu C, Wang H T
Department of Otorhinolaryngology Head and Neck Surgery, Chinese People's Liberation Army General Hospital, Beijing 100853, China.
Department of Otorhinolaryngology Head and Neck Surgery, Chinese People's Liberation Army General Hospital, Beijing 100853, China; Department of Otorhinolaryngology Head and Neck Surgery, Hainan Branch of Chinese People's Liberation Army General Hospital, Sanya 572000, China.
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2016 Jun 7;51(6):476-9. doi: 10.3760/cma.j.issn.1673-0860.2016.06.021.
Hereditary hemorrhagic telangiectasia(HHT) is an autosomal disorder characterized by hemorrhage and abnormal blood vessels. Spontaneous recurrent epistaxis is the most common manifestation, and the severity of nosebleed develops with age increasing. However, there is no effect treatment for HHT-related epistaxis until now. Recently, bevacizumab shows significant effect in the treatment of HHT and the related literatures are increasing gradually. This article will review the studies focused on bevacizumab in the treatment of HHT-related refractory nasal bleeding.
遗传性出血性毛细血管扩张症（HHT）是一种以出血和血管异常为特征的常染色体疾病。自发性反复鼻出血是最常见的表现，鼻出血的严重程度随年龄增长而加重。然而，迄今为止，尚无针对HHT相关性鼻出血的有效治疗方法。最近，贝伐单抗在治疗HHT方面显示出显著疗效，相关文献也在逐渐增多。本文将综述聚焦于贝伐单抗治疗HHT相关性难治性鼻出血的研究。
